some interesting articles, page-3

"Lupus: Peptide P140/LupuzorTM effectiveness confirmed

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus
erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers
led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg,
France.

The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the
disease.

Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the
peptide.

Now the final phase of clinical tests should soon confirm these results and contribute to the development of
a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants."


I have only been following the PYC forum for a short while, so I am not sure of the significance of this press release(dated Jan 2013).

Are you saying that the success of this trial at another organisation makes the PYC in-house lupus research redundant?